Inmune Bio Inc. CEO Raymond Tesi told BioWorld his firm is taking an “oncology-style” approach to Alzheimer’s disease (AD) as the firm tests next-generation tumor necrosis factor (TNF) inhibitor XPro-1595 against neuroinflammation.
BEIJING – Androgen receptor (AR) antagonist developer Kintor Pharmaceutical Ltd., of Suzhou, China, is going to provide its proxalutamide (GT-0918) to an ongoing clinical trial in male patients, led by U.S. firm Applied Biology Inc., in Brazil for COVID-19, after preliminary clinical research suggested a potential link between androgenetic alopecia and COVID-19 pathogenesis.
Nextcure Inc. won’t advance the non-small-cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage two portion of its phase I/II study of NC-318, a monoclonal antibody targeting Siglec-15 (S15), as a monotherapy. The data and decision prompted the company stock to shed more than half its value July 13 and several analysts to adjust their price targets downward.
Although details are yet to come, Equillium Inc.’s chief medical officer, Krishna Polu, told BioWorld that the company will move “urgently and expeditiously” to set up another experiment testing itolizumab in COVID-19 now that Bangalore, India-based partner Biocon Ltd. has unveiled positive phase II results with the CD6-targeting agent.
CAJICA, Colombia, and BEIJING – Last week Sinovac Biotech Ltd., of Beijing, announced the approval by Anvisa, the Brazilian health care surveillance agency, to start phase III trials to test the efficacy and safety of its inactivated COVID-19 vaccine being developed by Sinovac Life Sciences, a subsidiary of the Chinese company, in the Latin American country.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abeona, Atox, Center Laboratories, DBV, Gilead, Macrogenics, Sedana, Sosei, Tonix, Ziopharm.
A first-of-its-kind clinical trial conducted by digital health startup AppliedVR suggests the computer-based technology is both feasible and effective for treating chronic pain in a patient’s own home.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acer, Bayer, Biogen, Enanta, Ideaya, JS Innopharm.
RSS
